



Shield Therapeutics plc
 (“Shield” or the “Company” or the “Group”)

Results of 2026 Annual General Meeting

London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia (“ID/IDA”), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2026. The Board reports that all resolutions were passed: 1 to 12 passed as ordinary resolutions and 13 and 14 passed as special resolutions.

The following table shows the votes cast on each resolution:

	VOTES FOR	%	VOTES AGAINST	%	WITHHELD VOTES
Resolution 1	663,423,759	99.99%	83,973	0.01%	612,706
Resolution 2	663,165,096	99.96%	259,840	0.04%	695,502
Resolution 3	662,822,843	99.91%	602,093	0.09%	695,502
Resolution 4	663,131,934	99.96%	267,835	0.04%	720,669
Resolution 5	662,884,358	99.92%	540,585	0.08%	695,495
Resolution 6	663,146,757	99.96%	253,012	0.04%	720,669
Resolution 7	662,771,376	99.91%	628,393	0.09%	720,669
Resolution 8	663,346,163	99.97%	189,245	0.03%	585,030
Resolution 9	661,191,218	99.65%	2,342,764	0.35%	586,456
Resolution 10	660,806,346	99.56%	2,944,366	0.44%	369,726
Resolution 11	660,769,857	99.55%	2,978,561	0.45%	372,020
Resolution 12	658,773,200	99.24%	5,058,591	0.76%	288,647
Resolution 13	658,492,989	99.21%	5,225,392	0.79%	402,057
Resolution 14	658,549,598	99.26%	4,920,741	0.74%	650,099

Notes:

1. Number of shares in issue 1,069,524,125.
2. Details of the votes received on the resolutions are available on the Company’s website:
<https://shieldtherapeutics.com/financials>.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

For further information please contact:

Shield Therapeutics plc

Anders Lundstrom, CEO

Stephanie Hicks, Investor Relations

<https://shieldtherapeutics.com/link/PGXDzy>

www.shieldtherapeutics.com

+44 (0) 191 511 8500

Investorrelations@shieldtx.com

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel

+44 (0)20 7418 8900

Joint Broker

Cavendish Ltd

Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward

+44 (0)20 7220 0500

About Iron Deficiency and ACCRUFer®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a \$2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFer® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading **#1 branded prescription oral iron the market today** (data source - IQVIA Xponent PlanTrak).

ACCRUFer®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFer®/FeRACCRU®, including the product label, can be found at: www.ac crufer.com and www.ferac cru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFer®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFer® in the U.S. to include pediatric patients 10 years of age and older with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., to include pediatric patients 12 years of age and older and also have marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFer®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.

ACCRUFer®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFer®/FeRACCRU® are registered trademarks of Shield Therapeutics.